NASDAQ: ORKA

Oruka Therapeutics (ORKA) Stock Analysis & Forecast

Nov 13 close

$105.35+0.36 (+0.3%)

Gekko Brief

AI summaryNov 9 close

Oruka Therapeutics reported third quarter 2026 financial results this week, with EVERLAST-B Week 16 data showing 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, described as highly consistent with EVERLAST-A. The company also announced participation in multiple upcoming conferences. Separately, a filing showed Candriam S.C.A. trimmed its ORKA holdings by 3.9% during the third quarter.

ORKA closed at $104.56, up 1.7%, sitting above both its 50-day average of $88.48 and its 200-day average of $71.21, with the 50-day above the 200-day. The GekkoIndex reads 45.6, placing the stock in the Neutral zone, down 3.8 over five days. Gekko Fair Value stands at $107.52, putting price 2.8% below that mark.

Oruka's next earnings report is scheduled for 11 November 2026, just 116 days away and within a typical 20-trading-day hold; the prior quarter's report produced a 5.9% reaction, with 5 beats across 8 quarters. No insider, Congress or unusual options activity appears in the current windows, though one billionaire holder and one trailblazer holder are noted. Analyst coverage from 11 firms is unanimously rated buy, with a consensus target of $156.17. Seasonality from this point has averaged -5.1% over the next 20 trading days across 5 years, rising in 2 of them, a pattern worth noting given the imminent earnings date.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Oruka Therapeutics price vs fair value

$108.36$105.35Nov ’25May ’26Nov ’26
Close $105.35200-day averageGekko Fair Value $108.36

Oruka Therapeutics quick facts

Market cap
$7.15B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$2.12
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
-0.17
Volume
679,677 avg 997,437
1-year return
+272.3%
Typical daily move
±5.7%
Typical 20-day move
±7.8%
50-day average
$89.68
200-day average
$72.65
Next earnings
Mar 11
Shares outstanding
67.82M
52-week range
$25.23$115.52

Oruka Therapeutics swing-trade checklist

Oruka Therapeutics scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $105.35 is above the 50-day ($89.68) and 200-day ($72.65) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    48.2, Neutral

    Reading 48.2 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    2.8% below

    Price is within 5% of Gekko Fair Value (2.8% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 116 days

    Next report Mar 11, 2027, 116 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +0.2% on average

    From this point in the calendar, the next 20 trading days averaged +0.2% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Oruka Therapeutics stock chart and price history

Oruka Therapeutics closed at $105.35 on Nov 13, 2026, +272.3% over the past year, inside a 52-week range of $25.23 to $115.52.

Close50-day average200-day averageVolume
Oruka Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$20$40$60$80DecJan 2026FebMarAprMayJunJulAugSepOctNov105.35

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+42.6%
3 months
−6.5%
6 months
+70.1%
1 year
+272.3%
The full ORKA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ORKA in Gekko

Follow Oruka Therapeutics through every session

Put ORKA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ORKA in GekkoFree for 7 days. No credit card required.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biopharmaceutical company working on monoclonal antibody treatments for psoriasis and related inflammatory and immunology conditions. Its work centers on a set of drug candidates aimed at underlying immune pathways linked to these diseases, with the goal of offering new treatment options to patients affected by them.

The company's pipeline includes ORKA-001, aimed at the p19 subunit of interleukin-23 and currently in a phase 2a trial for psoriasis, and ORKA-002, which targets both interleukin-17A and interleukin-17F and is being tested in a phase 2 trial for psoriasis, psoriatic arthritis, and other conditions. It is also developing ORKA-003, aimed at a pathway that has not been disclosed, along with ORKA-021, a regimen that combines ORKA-002 and ORKA-001 in sequence.

Oruka Therapeutics is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ under the ticker ORKA.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
orukatx.com

Oruka Therapeutics GekkoIndex: the smart money zone

Oruka Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.2, in the Neutral zone, down 0.3 points over five sessions.

010048.2Neutral

Down 0.3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying43+3.1%+9.3%+3.6%−3.2%
Accumulation180+0.6%+1.0%+0.5%−2.8%
Neutral (current zone)413+2.6%+4.4%+10.8%+32.3%
Distribution56+1.6%+8.2%+13.2%+25.7%
Selling10−7.5%−9.2%−12.0%−8.1%

Average ORKA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ORKA price, zone by zone.Track ORKA in Gekko

Is Oruka Therapeutics stock overvalued? Gekko Fair Value

Oruka Therapeutics trades 2.8% below Gekko Fair Value of $108.36, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Oruka Therapeutics shares are worth, recalculated every trading day.

$108.36

Gekko Fair Value, Nov 14, 2026

2.8% below fair value · About fair value

At the end of Aug 2026 the price was 30.4% below the estimate.

Gekko Fair ValueShare price, month end
$108$105Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ORKA in Gekko

Oruka Therapeutics insider and Congress trading

No open-market insider purchases were filed for Oruka Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ORKA in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ORKA insider filing, plotted on the chart in Gekko.Open ORKA in Gekko

Congress trades last 90 days

No trades in ORKA were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ORKA, plotted on the chart in Gekko.Open ORKA in Gekko

Hedge funds and billionaires quarter ended Sep 30

2of the funds Gekko tracks hold ORKA.

0added0opened2trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Oruka Therapeutics earnings: next date and track record

Oruka Therapeutics reports on Mar 11, 2027 (116 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±5.9%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−8.0%Nov ’24+0.8%Mar ’25−1.7%May ’25+6.6%Aug ’25−6.5%Nov ’25+16.2%Mar ’26−1.2%May ’26+5.9%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 10, 2026−$0.55
est −$0.51
−7.3%——+5.9%
May 13, 2026−$0.48
est −$0.54
+11.1%——−1.2%
Mar 12, 2026−$0.45
est −$0.62
+26.9%——+16.2%
Nov 12, 2025−$0.55
est −$0.56
+1.8%——−6.5%
Aug 11, 2025−$0.46
est −$0.48
+4.2%——+6.6%
May 14, 2025−$0.40
est −$0.44
+9.1%——−1.7%
Mar 6, 2025−$0.54
est −$0.41
−31.7%——+0.8%
Nov 13, 2024−$1.46
est −$0.32
−356.2%——−8.0%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Oruka Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Oruka Therapeutics is $156.17, +48.2% from the last close, from 12 firms rating the stock in the last 90 days.

$156.17consensus 12-month target, +48.2% from the last close
Low $105High $200
Buy12
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 12 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Stifel NicolausBuy, reiterated$150+42.4%
Nov 10Piper SandlerBuy, maintained$180+70.9%
Nov 10H.C. WainwrightBuy, reiterated$120+13.9%
Nov 10BarclaysBuy, maintained$160+51.9%
Nov 10UBSBuy, maintained$130+23.4%
+10.8%average 20-day move after past Neutral readings
+0.2%average move over the next 20 trading days in the last 5 years
±5.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Oruka Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Oruka Therapeutics averaged +0.2% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−6.1%2021+11.7%2022+1.1%2023−8.6%2024+11.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.1%3 of 5
Next 10 trading days−2.6%3 of 5
Next 15 trading days−0.7%3 of 5
Next 20 trading days+0.2%3 of 5
Next 30 trading days−3.2%2 of 5

For scale, ORKA’s typical 20-trading-day move in either direction is about 7.8%.

Oruka Therapeutics market cap and key statistics

Oruka Therapeutics’s market cap is $7.15B and revenue of $0 over the last twelve months.

Valuation

Market cap
$7.15B
EPS, TTM
−$2.12
Gekko Fair Value
$108.36

Trading

Volume
679,677
Avg volume, 20 days
997,437
52-week high
$115.52
52-week low
$25.23
Shares outstanding
67.82M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-18.1%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
-0.17
Typical daily move
±5.7%
Typical 20-day move
±7.8%

Oruka Therapeutics stock news this week

2 headlines about Oruka Therapeutics from the past week, newest first, each linking to the publisher.

Oruka Therapeutics peers

Oruka Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Oruka Therapeutics stock FAQ

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is $7.15B at the Nov 13, 2026 close of $105.35, with 67.82M shares outstanding.

What is the Oruka Therapeutics stock forecast?

The consensus analyst 12-month price target for Oruka Therapeutics is $156.17, +48.2% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Oruka Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Oruka Therapeutics is about fair value: the Nov 13, 2026 close of $105.35 is 2.8% below Gekko Fair Value of $108.36. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Oruka Therapeutics report earnings next?

Oruka Therapeutics is expected to report on Mar 11, 2027 (116 days away). Analysts expect earnings of −$0.78 per share. Oruka Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 5.9% on average across the report.

What is Oruka Therapeutics’s 52-week high and low?

Oruka Therapeutics’s 52-week high is $115.52 and its 52-week low is $25.23; it closed at $105.35 on Nov 13, 2026, +272.3% over the past year.

Is Oruka Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Oruka Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.